Comparative Study of Clinical Trials Regulatory Oversight in Burkina Faso and Senegal
- 1 Laboratory of Galenic and Legislation, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta DIOP, Dakar, Senegal
Abstract
Introduction: Clinical trials issue is both legal and ethical. Pharmaceutical firms in developed countries are relocating more and more their tests in African continent, where lack of legislation weakens the fact to standardize clinical trials. Our objective was to make a retrospective comparative study on regulatory oversight of clinical trials in Burkina Faso and Senegal, from February 22th, to 1 st of June 2016. Methodology: Data collection was performed by a literature review and interviews. Data analysis was done by comparing monitoring systems using indicators such as existence of a legal framework, mode of assessment and licensing, monitoring of clinical trials. Results: Clinical trials are regulated in Burkina Faso and Senegal. During the study, 34 authorizations were issued, and three sites were visited and one inspection made. The processing time of an application file is estimated at 110 days. As for Senegal, scientific evaluation by experts is not systematic. The processing time of a file is estimated at 40 days, and no inspection or site visit has been recorded. Conclusion: Burkina Faso regulatory oversight of clinical trials is implemented in accordance with GCP. Senegal hasn’t developed specific texts for clinical trials, and NEHR issues an ethical and scientific opinion. NRA has adopted ICH-GCP, without any mandate for assessing protocol. However, Burkina Faso’s current system combined with that of Senegal, could contribute to developing an effective model of regulatory oversight of clinical trials in West African Economic and Monetary Union, for public health benefit.
- Chippaux, J. P. (2002). Unscrupulous Medicine. Africa the Guinea Pig of Big Pharma. The Diplomatic World.
- Chippaux, J. P. (2004). Practice of Clinical Trials in Africa (p. 27). Didactic Collection. IRD Editions.
- Diagne, S. A. (2019). Evaluation of Senegal’s Pharmaceutical Regulatory System. Draft Report. https://www.cners.sn/public/docs/1587397053.pdf
- Diallo, A., & Sokhna, C. (2018). Clinical Trials in the Niakhar Observatory. In Niakhar, Memories and Perspectives (pp. 385-388). IRD Editions. https://books.openedition.org/irdeditions/31727?lang=en https://doi.org/10.4000/books.irdeditions.31727
- Diarra, O. (2007). The Practice of Clinical Trials in Senegal. DEA Health Law Category Biology and Medicine. Cheikh Anta Diop University of Dakar.
- Fagot-Largeault (2002). Ethics of Scientific Investigation of Human Beings. In Y. Michaud (Ed.), University of All Knowledge It. Philosophy and Ethics (pp. 68-86). Paris, Odile Jacob, Coll. Pockets.
- Guidelines (ICH1 E6): International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (Consulted on 03/22/2016 at 12 p.m.).
- Maiga, D. (2012). Development of an Approach to the Regulation of Clinical Trials in the Context of Developing Countries: The Case of Mali. Thesis in Public Health, Montreal University, Faculty of Graduate and Postdoctoral Studies.
- Parizeau, M. H. (2000). Research Ethics Committees and Pharmaco-Politics: The Case of Quebec (pp. 82-95).
- Sardan, J. P. O. (2004). Local and Quality Medicine for Africa. The Diplomatic World, February.
- WHO Good Clinical Practice Guidelines [Online] Consulted on 10/03/2016 12 Noon.